NCT02976909View on ClinicalTrials.gov

Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Paclitaxel+Cisplatin+5fluorouracil

Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Yuhong Li

OTHER

NCT02976909 - Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter